Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab for second- or later-line advanced hepatocellular carcinoma after PD-1 inhibitor
ChiCTR2600124381Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guilin Medical University
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of QL1706 in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of Guilin Medical University. Primary endpoint: Objective response rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600124381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124381.